Annovex Pharma, Inc., Lorton, VA
Is Annovex Pharma, Inc. an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Annovex Pharma, Inc. in Lorton, VA, first registered Oct 14, 2021 and most recently registered Feb 13, 2026. FDA lists its last inspection as Jun 3, 2026, with a Form FDA 483 issued; FDA lists the action on that inspection as “Open”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Lorton, VA
- Initial registration
- Oct 14, 2021
- Most recent registration
- Feb 13, 2026
- Last inspection
- Jun 3, 2026
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Open
- Intends to compound sterile drugs from bulk substances
- Yes
- Earlier inspections
- FDA notes that an earlier inspection led to a Form 483, warning letter or other action
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Annovex Pharma, Inc., Lorton, VA, a 503B facility, with 3 listed actions, including 2 Form 483s and 1 warning letter (2024 to 2026).
| Document | |||
|---|---|---|---|
| Jun 18, 2026 | Amended Form 483 | Amended 483 Issued 06/18/2026 | fda.gov |
| Mar 5, 2025 | Warning letter | Warning Letter Issued 03/05/2025 | fda.gov |
| Sep 6, 2024 | Form 483 | 483 Issued 09/06/2024 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Annovex Pharma, Inc., Lorton, VA (FEI number 3020928491), matched to this page by exact name, city and state. It lists 1 inspection: 1 OAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Sep 6, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3020928491 | 1248991 |
Form 483s FDA has published for this site
- Jul 3, 2026: Form 483 to Annovex Pharma, Inc., published Jul 22, 2026. fda.gov
- Sep 6, 2024: Form 483 to Annovex Pharma, Inc., published Oct 2, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 9 numbered observations in all, across 2 inspections ending Sep 6, 2024 to Jun 3, 2026. Each observation is quoted from the PDF as FDA numbered it. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection May 27, 2026 to Jun 3, 2026: 2 observations
- Firm on the cover
- Annovex Pharma, Inc., 7403 Lockport Pl Ste C-D, Lorton, VA 22079-1569
- FEI number
- 3020928491
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 11155 Dolfield Boulevard, Suite 117 Owings Mills, MD 21117
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
Specifically, your firm failed to ensure that the laminar airflow hoods used for the production of sterile and non-sterile drug products were maintained in a state of adequate control. During the <Redacted B4> cleanroom certification conducted on January 28, 2026, a <Redacted B4> laminar airflow hoods at your facility were found to be operating outside the acceptable airflow velocity range at the time of certification, as documented by the as-found FAIL designation in Certification Report #02647-20260128RTO1 :
<Redacted B4>
Your firm did not initiate an investigation or quality related event in response to these findings and did not conduct a product impact assessment for sterile and non-sterile drug products produced in these laminar airflow hoods since the previous <Redacted B4> certification in July 2025.
feUe1.i,iiR~
AMENDMENT 1
Observation 2
Records are not maintained so that data therein can be reviewed at least annually to evaluate the quality standards of each drug product to determine the need for changes in specifications or manufacturing or control procedures.
Specifically, your firm has not conducted annual product reviews for any drug product in your portfolio. Your Quality Assurance Manager confirmed that no annual product reviews have been completed and that the standard operating procedure governing the conduct of annual product reviews has not been approved and remains in draft form.
The following drug products have been in commercial production for more than one year without an annual product review being conducted:
• Lorazepam 0.25 mg/0.125 mL Oral Solution -commercially produced since November 28, 2023 <Redacted B4> batches to date)
• Lorazepam 0.5 mg/0.25 mL Oral Solution -commercially produced since November 28, 2023 <Redacted B4> batches to date)
• Phenylephrine Hydrochloride Injection 0.1 mg/mL -commercially produced since January 29, 2024, <Redacted B4> batches to date)
Inspection Aug 26, 2024 to Sep 6, 2024: 7 observations
- Firm on the cover
- Annovex Pharma, Inc., 7403 Lockport Pl Ste C-D, Lorton, VA 22079-1569
- FEI number
- 3020928491
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 11155 Dolfield Boulevard, Suite 117 Owings Mills, MD 21117
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.
Specifically, your firm's media fill program is inadequate as it does not provide an assurance that your staff can manufacture drug product under aseptic conditions. The following deficiencies were identified:
A -You did not incubate all integral units during the <Redacted B4> incubation period for Media Fills performed at your site. For example, during the Media Fill performed on 07/29/2024, <Redacted B4> syringes were filled, but only <Redacted B4> randomly selected <Redacted B4> incubated. Furthermore, there is no scientific justification provide for not incubating all <Redacted B4> integral units.
B- You did not ensure that the purchased media powder used for Media Fill studies is growth promoted and suitable for its intended use, prior to use. For example, on 01/10/2024, during an Aseptic Process Simulation, the in-house prepared media (lot# <Redacted B4> was not inoculated with the USP-recommended microorganism. This step is necessaiy to contnm that the media can promote microbial growth effectively.
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure ofa batch or any of its components to meet any of its specifications whether or not the batch has been aheady distributed.
Specifically,
A- Microbial growth was observed in 100 syringes (units <Redacted B4> for the media fill performed on 01/04/2024. On 01/05/2024, your quality unit discarded all 100 of <Redacted B4> syringes that showed microbial growth without providing scientific justification. Additionally, surface and gloved fingeriip samples obtained during this process were not incubated beyond day <Redacted B4>. You did not make an attempt to identify the organism(s) in the turbid units or assess the impact on blended drug products produced since the last successful Media Fill.
B- You did not initiate an investigation or deviation for the HEPA filter leak test failure in the classified Buffer Room n, (ISO 7) observed during the Dec 2023 receriification. In addition, you do not have a procedure in place to evaluate HEP A filter failures or patches nor product impact on items that are potentially affected.
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically, unidirectional airflow was not verified under dynamic conditions representative of your typical production process. Smoke studies conducted in July 2024 in your ISO 5 laminar air flow hoods did not show manipulations or conditions performed (Sterile connection to bulk solution/bag, initial setup of repeater pump in use) that would be representative of the dynamic process used in actual production processes.
Observation 4
Written procedures are lacking which describe in sufficient detail the storage of components, diug product containers and closures.
Specifically, there is no temperature monitoring in the warehouse where raw material and blended drugs products are stored. For example, there are <Redacted B4> units of Phenylephrine HCl 25 mg in 0.9% Sodium Chloride 250 mL Bag, lot# <Redacted B4> 24.08.00000014 (with storage temperature specifications of <Redacted B4> to <Redacted B4> stored in the blended product storage area.
Observation 5
Records associated with drug product production and control and within the retention period for such records, were not made readily available for authorized inspection.
Specifically, Media Fill records from 06/27/2023, 6/28/2023 and 7/10/2023 were unavailable and could not be retrieved for review.
Observation 6
The labels of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A) of the Federal Food, Dmg, and Cosmetic Act (FD&C Act).
Specifically, the following information is not found on your drug product labels:
A list of active and inactive ingredients, identified by established name and the quantity or proportion of each ingredient.
• Examples of your drug product labels that do not contain this information.
• Lorazepam 0.25 mg/0.125 ml and 0.5 mg/0.25 ml oral concentrates; • Mo1phine Sulfate 5 mg/0.25 ml oral concentrate; and • Oxycodone HCl 10 mg/0.5 ml, 5 mg/0.25 ml, 2.5 mg/0.125 ml oral solutions .
Observation 7
Your outsourcing facility did not submit a repo1t to FDA identifying the di11gs compounded during the previous six month period.
Specifically, the following products were compounded and not identified on your product report dated June 2024.
• Heparin 4 units/mL in I 000 ml • Phenylephrine I 00 mcg/ml in IO ml syringes • Phenylephrine HCl 25 mg in 250 ml
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Annovex Pharma, Inc.). That is not a finding beyond this index’s search.
The Annovex Pharma, Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
FDA NDC listings
FDA’s NDC Directory files, read Nov 15, 2026, list 5 products naming semaglutide and tirzepatide under the labeler name “ANNOVEX PHARMA, INC.”, matched to this facility page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (5). The compounded product reports cover FDA reporting periods 2025-1 to 2025-1.
FDA’s NDC files name the labeler, not the site, so a firm with more than one location shows the same listings on each location’s page.
| Reporting periods | ||||||||
|---|---|---|---|---|---|---|---|---|
| 82396-300 | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 1 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
| 82396-302 | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 2.5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
| 82396-305 | Semaglutide | Semaglutide | INJECTION, SOLUTION | SUBCUTANEOUS | 5 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
| 82396-350 | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 10 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
| 82396-351 | Tirzepatide | Tirzepatide | INJECTION, SOLUTION | SUBCUTANEOUS | 20 mg/1 mL | OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) | 2025-1 | Compounded drugs |
FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.
FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- FDA National Drug Code Directory (download files)
- FDA: NDC product file definitions
- openFDA drug NDC endpoint (count cross-check)
Records last pulled Nov 15, 2026. Every entry links to the original public record.